Table 1.
Summarization of clinico-pathologic factors of entire patients and according to the subgroups stratified by the cholesterol level of 170 mg/dL cut-off
| Entire patients (n = 244) | High PCL group (n = 72) | Low PCL group (n = 172) | p value | |
|---|---|---|---|---|
| Median (IQR) or Number (percent) | ||||
| Age (y) | 59.0 (52.0–68.0) | 57.5 (52.0–67.0) | 60.0 (51.3–68.8) | 0.981 |
| BMI (kg/m 2) | 23.0 (21.0–24.8) | 23.5 (21.8–42.8) | 22.9 (20.8–24.9) | 0.239 |
| Sex (male) | 185 (75.8%) | 50 (69.4%) | 135 (78.5%) | 0.091 |
| Serum Albumin (g/dL) | 4.0 (3.5–4.3) | 4.3 (3.9–4.4) | 3.9 (3.4–4.2) | < 0.001 |
| Hemoglobin (g/dL) | 12.1 (10.6–13.6) | 13.1 (11.7–14.7) | 11.8 (10.3–13.1) | < 0.001 |
| Platelet (k/dL) | 274.5 (132.3–173.8) | 271.5 (212.5–320.5) | 299.8 (222.0–378.8) | 0.038 |
| PLC (mg/dL) | 156.0 (132.3–173.8) | 190 (178–205.8) | 139.1 (126.3–157.8) | |
| Corrected calcium (mg/dL) | 9.2 (8.9–9.7) | 9.4 (9.0–9.8) | 9.5 (8.8–9.6) | |
| ECOG score (≥2) | 79 (32.4%) | 22 (30.6%) | 57 (33.1%) | 0.765 |
| Diabetes mellitus | 60 (24.7%) | 14 (19.7%) | 46 (26.7%) | 0.326 |
| Hypertension | 120 (49.6%) | 33 (46.5%) | 87 (50.9%) | 0.574 |
| Tumor size (cm) | 8.0 (5.6–10.5) | 6.5 (5.0–9.5) | 8.7 (6.1–11.0) | 0.407 |
| Clinical stage (≥3) | 138 (56.6%) | 32 (44.4%) | 106 (61.6%) | 0.059 |
| Metastatic sites | 0.541 | |||
| Lung | 78 (32.0%) | 23 (31.9%) | 55 (32.0%) | |
| Liver | 7 (2.7%) | 1 (1.4%) | 5 (2.9%) | |
| Bone | 24 (9.8%) | 10 (13.9%) | 14 (8.1%) | |
| Non-regional LNI | 2 (1.0%) | 0 (0%) | 2 (1.2%) | |
| Adrenal gland | 8 (3.3%) | 4 (5.6%) | 4 (2.3%) | |
| Multiple metastasis | 10 (4.1%) | 3 (4.2%) | 7 (4.1%) | |
| Information missing | 108 (44.3%) | 33 (45.8%) | 75 (43.6%) | |
| Miscellaneous | 2 (1.0%) | 0 (0%) | 2 (1.2%) | |
| Pathologic stage | 0.060 | |||
| pT1 | 60 (24.6%) | 24 (33.3%) | 36 (20.9%) | |
| pT2 | 36 (14.8%) | 11 (15.3%) | 25 (14.5%) | |
| pT3 | 117 (48.0%) | 33 (45.8%) | 84 (48.8%) | |
| pT4 | 31 (12.7%) | 4 (5.6%) | 27 (15.7%) | |
| Fuhrman grade | 0.424 | |||
| ≤ 2 | 34 (13.9%) | 12 (16.7%) | 22 (12.8%) | |
| ≥ 3 | 210 (86.1%) | 60 (83.3%) | 150 (87.2%) | |
| Histologic subtype | 0.214 | |||
| Clear cell | 213 (87.3%) | 67 (93.1%) | 146 (84.9%) | |
| Papillary | 13 (5.3%) | 2 (2.8%) | 11 (6.4%) | |
| Chromophobe | 4 (1.6%) | 0 (0%) | 4 (2.3%) | |
| Collecting duct | 5 (2.0%) | 1 (1.4%) | 4 (2.3%) | |
| Unclassified | 9 (3.7%) | 2 (2.8%) | 7 (4.1%) | |
IQR interquartile range, PCL preoperative cholesterol level, BMI body mass index, ECOG Eastern Cooperative Oncology Group, LNI lymph node invasion